0.29
+0.0062(+2.15%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.28 |
| Day High | 0.3 |
| Day Low | 0.28 |
| 52-Week High | 2.08 |
| 52-Week Low | 0.16 |
| Volume | 2.44M |
| Average Volume | 9.77M |
| Market Cap | 17.84M |
| PE | -0.31 |
| EPS | -0.96 |
| Moving Average 50 Days | 0.35 |
| Moving Average 200 Days | 0.46 |
| Change | 0.01 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.01 as of March 09, 2026 at a share price of $0.295. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $6.92 as of March 09, 2026 at a share price of $0.295.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
GlobeNewswire Inc.
Feb 25, 2026 12:30 PM GMT
Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization trackingHOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
GlobeNewswire Inc.
Jan 22, 2026 12:45 PM GMT
Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceut
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
GlobeNewswire Inc.
Jan 21, 2026 9:15 PM GMT
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today an